A formal Phase 2 trial was completed in 2009, but over 15 years later, the results have never been published, another major red flag suggesting it failed to prove effective or safe
It is knowing which patient needs a GLP-1 and which one needs a workup, how to titrate through the nausea window without losing the patient, how to protect lean mass during rapid loss, how to screen for the contraindications that matter, and how to tell a patient honestly what an adjunct will and will not do for them
Another study highlighted TB-500s ability to enhance keratinocyte motility, integrin-linked kinase signaling, and angiogenic capacity[7]
It easily crosses the blood-brain barrier, allowing it to effectively influence various brain functions
In particular, glabellar frown lines become indented between the brows
These findings support the appropriateness of considering biologic therapies for patients with low BSA and indicators of high disease burden